Trial Summary
What is the purpose of this trial?
This study is to find out if the Attention Processing Training program is a potential treatment for brain fog symptoms, reported by people with Long-Covid. Also investigating the feasibility of completing this program virtually.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It might be best to discuss this with the trial coordinators or your doctor.
What data supports the effectiveness of the treatment Attention Training and Multimodal Affect Recognition Training (MMART) combined with Attention Training for Long COVID?
Research shows that Attention Training Technique (ATT) can improve attention control and flexibility, which may help with attention issues in Long COVID. Additionally, training in emotion regulation has been shown to enhance psychological well-being and resilience, suggesting potential benefits for emotional and cognitive challenges faced by Long COVID patients.12345
Is Attention Training safe for humans?
Attention Training, including techniques like the Attention Training Technique (ATT) and Online Contingent Attention Training (OCAT), has been studied in healthy participants and those with conditions like depression and anxiety. These studies suggest that the training is generally safe, as no adverse effects were reported in the research.23567
How does the Attention Training treatment for Long COVID differ from other treatments?
The Attention Training treatment for Long COVID is unique because it combines Multimodal Affect Recognition Training (MMART) with attention strategies to help patients recognize and interpret emotions from different sources, like audio and visual cues. This approach is novel as it focuses on improving cognitive and emotional processing, which is not typically addressed by standard treatments for Long COVID.89101112
Research Team
Shira Cohen-Zimerman, PhD
Principal Investigator
Shirley Ryan AbilityLab
Elliot Roth, MD
Principal Investigator
Shirley Ryan AbilityLab
Eligibility Criteria
This trial is for adults aged 18-65 who have had COVID-19 and are experiencing 'brain fog' that affects daily life. Participants must have attentional deficits, be able to use a keyboard, consent independently, and communicate in English. Those with severe depression, recent chemotherapy or radiation treatment, active substance abuse, or certain pre-existing neurological conditions cannot join.Inclusion Criteria
Exclusion Criteria
Trial Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive either the Attention Training or Music Program intervention for 4 weeks
Follow-up
Participants are monitored for changes in attention test scores and completion of study tasks
Optional Attention Training
Participants in the Delayed Attention Training group have the option to complete the Attention Training after initial assessments
Treatment Details
Interventions
- Attention Training (Behavioural Intervention)
Find a Clinic Near You
Who Is Running the Clinical Trial?
Shirley Ryan AbilityLab
Lead Sponsor
Dr. Pablo Celnik
Shirley Ryan AbilityLab
Chief Executive Officer since 2023
MD from University of Buenos Aires Faculty of Medical Sciences
Dr. James Sliwa
Shirley Ryan AbilityLab
Chief Medical Officer since 2021
DO